Trial · NCT00296400

Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease

NCT00296400, Phase 2, Completed, AstraZeneca; results first posted 2010-12-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease. Trials, record NCT00296400. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00296400

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
NCT number: NCT00296400
Status: Completed
Phases: Phase 2
Enrollment: 237 participants, actual
Lead sponsor: AstraZeneca
Conditions: Hyperlipidemia
Interventions: Rosuvastatin, Atorvastatin
First posted: 2006-02-27
Last updated: 2011-06-16
Results first posted: 2010-12-30

Source ClinicalTrials.gov

Registered outcomes72

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Urinary Protein/Creatinine Ratio at Week 52 [LOCF]	Assessed at baseline and Week 52 (LOCF)	Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Secondary	Urinary Protein/Creatinine Ratio at Week 26.	Assessed at baseline and Week 26	Urinary protein/creatinine ratio (mg/g) =urine protein concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine protein/creatinine ratio over baseline urine protein/creatinine ratio.
Secondary	Urinary Albumin/Creatinine Ratio at Week 26	Assessed at baseline and Week 26	Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 26 urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Secondary	Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]	Assessed at baseline and Week 52 [LOCF]	Urinary albumin/creatinine ratio (mg/g) =urine albumin concentration (mg/dL)/ urine creatinine concentration (g/dL). Outcome measure is the ratio of Week 52 \[LOCF\] urine albumin/creatinine ratio over baseline urine albumin/creatinine ratio.
Secondary	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26	Assessed at baseline and Week 26	The change from baseline in eGFR at Week 26 is the Week 26 value minus baseline value.
Secondary	Change From Baseline in eGFR at Week 52 [LOCF]	Assessed at baseline and Week 52 [LOCF]	The change from baseline in eGFR at Week 52 \[LOCF\] is the Week 52 value or last observation carried forward minus baseline value.
Secondary	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.	baseline and 26 weeks	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Secondary	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.	52 weeks	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Secondary	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26	Baseline and 26 weeks	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 26. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)
Secondary	Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C	52 weeks	Correlation of changes from baseline in urinary protein/creatinine ratio with percent change from baseline in lipids and lipoprotein concentrations at Week 52. (Correlation values range from -1 to +1. -1 indicates a perfect negative linear relationship while a +1 indicates a perfect linear positive relationship. A value of zero indicates no relationship.)

1 to 10 of 72Source ClinicalTrials.gov

See all 72 registered outcomes

Outcomes72

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Urinary Protein/Creatinine Ratio at Week 52 [LOCF]	Assessed at baseline and Week 52 (LOCF)	ratio	GEOMETRIC_MEAN
SECONDARY	Urinary Protein/Creatinine Ratio at Week 26.	Assessed at baseline and Week 26	ratio	GEOMETRIC_MEAN
SECONDARY	Urinary Albumin/Creatinine Ratio at Week 26	Assessed at baseline and Week 26	ratio	GEOMETRIC_MEAN
SECONDARY	Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]	Assessed at baseline and Week 52 [LOCF]	ratio	GEOMETRIC_MEAN
SECONDARY	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 26	Assessed at baseline and Week 26	mL/min	MEAN
SECONDARY	Change From Baseline in eGFR at Week 52 [LOCF]	Assessed at baseline and Week 52 [LOCF]	mL/min	MEAN
SECONDARY	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 26.	baseline and 26 weeks	Correlation coefficient	NUMBER
SECONDARY	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Total Cholesterol [TC] at Week 52.	52 weeks	Correlation coefficient	NUMBER
SECONDARY	Correlation of Changes From Baseline in Urinary Protein/Creatinine Ratio With Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 26	Baseline and 26 weeks	Correlation coefficient	NUMBER
SECONDARY	Correlation of Changes From Baseline inUrinary Protein/Creatinine Ratio With Percent Change From Baseline in LDL-C	52 weeks	Correlation coefficient	NUMBER

1 to 10 of 72Source ClinicalTrials.gov

See all 72 outcomes

Results by group216

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Urinary Protein/Creatinine Ratio at Week 52 [LOCF]	Rosuvastatin 10 mg	0.938	95% Confidence Interval 0.725 to 1.212	ratio
Urinary Protein/Creatinine Ratio at Week 52 [LOCF]	Rosuvastatin 40 mg	1.082	95% Confidence Interval 0.927 to 1.262	ratio
Urinary Protein/Creatinine Ratio at Week 52 [LOCF]	Atorvastatin 80 mg	0.759	95% Confidence Interval 0.636 to 0.905	ratio
Urinary Protein/Creatinine Ratio at Week 26.	Rosuvastatin 10 mg	0.932	95% Confidence Interval 0.721 to 1.203	ratio
Urinary Protein/Creatinine Ratio at Week 26.	Rosuvastatin 40 mg	1.057	95% Confidence Interval 0.898 to 1.244	ratio
Urinary Protein/Creatinine Ratio at Week 26.	Atorvastatin 80 mg	0.762	95% Confidence Interval 0.631 to 0.921	ratio
Urinary Albumin/Creatinine Ratio at Week 26	Rosuvastatin 10 mg	0.850	95% Confidence Interval 0.631 to 1.143	ratio
Urinary Albumin/Creatinine Ratio at Week 26	Rosuvastatin 40 mg	0.946	95% Confidence Interval 0.789 to 1.135	ratio
Urinary Albumin/Creatinine Ratio at Week 26	Atorvastatin 80 mg	0.731	95% Confidence Interval 0.601 to 0.889	ratio
Urinary Albumin/Creatinine Ratio at Week 52 [LOCF]	Rosuvastatin 10 mg	0.879	95% Confidence Interval 0.652 to 1.185	ratio

1 to 10 of 216Source ClinicalTrials.gov

See all 216 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Rosuvastatin 10 mg	70
Overall Study	STARTED	Rosuvastatin 40 mg	87
Overall Study	STARTED	Atorvastatin 80 mg	80
Overall Study	COMPLETED	Rosuvastatin 10 mg	53
Overall Study	COMPLETED	Rosuvastatin 40 mg	69
Overall Study	COMPLETED	Atorvastatin 80 mg	67
Overall Study	NOT COMPLETED	Rosuvastatin 10 mg	17
Overall Study	NOT COMPLETED	Rosuvastatin 40 mg	18
Overall Study	NOT COMPLETED	Atorvastatin 80 mg	13

Source ClinicalTrials.gov

Adverse events84

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nausea	Gastrointestinal disorders	Rosuvastatin 10 mg	2	69
other	Nausea	Gastrointestinal disorders	Rosuvastatin 40 mg	6	87
other	Nausea	Gastrointestinal disorders	Atorvastatin 80 mg	0	80
other	Nasopharyngitis	Infections and infestations	Rosuvastatin 10 mg	3	69
other	Nasopharyngitis	Infections and infestations	Rosuvastatin 40 mg	6	87
other	Nasopharyngitis	Infections and infestations	Atorvastatin 80 mg	7	80
other	Bronchitis	Infections and infestations	Rosuvastatin 10 mg	4	69
other	Bronchitis	Infections and infestations	Rosuvastatin 40 mg	0	87
other	Bronchitis	Infections and infestations	Atorvastatin 80 mg	0	80
other	Blood Creatine Phosphokinase Increased	Infections and infestations	Rosuvastatin 10 mg	3	69

1 to 10 of 84Source ClinicalTrials.gov

See all 84 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Rosuvastatin 10 mg
Total, all-cause mortality	Rosuvastatin 40 mg
Total, all-cause mortality	Atorvastatin 80 mg
Total, other adverse events	Rosuvastatin 10 mg	15	69
Total, other adverse events	Rosuvastatin 40 mg	16	87
Total, other adverse events	Atorvastatin 80 mg	17	80
Total, serious adverse events	Rosuvastatin 10 mg	10	69
Total, serious adverse events	Rosuvastatin 40 mg	6	87
Total, serious adverse events	Atorvastatin 80 mg	5	80

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
25660356	DERIVED	PubMed
38018702	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00296400

GET https://conductscience.org/api/trials/v1/NCT00296400/registered?page=2

API reference For AI assistants